Inclusion Criteria:

- All races are eligible for entry into the Study.

- All patients must have been histologically documented (by a punch biopsy) for
dysplastic nevi with moderate to severe dysplasia (DMN). A similar biopsy proven DMN
that will serve as the control needs to be available.

- Patients must be healthy and active in normal pursuits of life and be able to provide
informed written consent.

- Localized dermatological conditions like psoriasis or actinic keratosis will not be
an exclusion criteria.

- Patients must be ambulatory with an ECOG status < 2; they will not be hospitalized as
part of the Study.

- All patients in this study will have, in addition to a normal clinical examination, a
thorough skin examination. Whenever possible, periodic photographs of their lesions
will be taken. Additional tests for all patients within 30 days of the initiation of
topical application include urinalysis, a liver function test (LFT), and blood tests
for complete blood count (CBC), BUN, and creatinine.

Exclusion Criteria:

- Women who are pregnant and/or nursing will be excluded. A pregnancy test will be
performed on each pre-menopausal woman within two days of entry into the Study, and a
negative pregnancy test must be recorded on the case report form prior to initiating
use of the topical application.

- Patients who are being treated for other chronic debilitating diseases (cardiac,
pulmonary, or any other organ specific diseases).

- Immuno-suppressed patients, either due to chemotherapy and radiation therapy or known
immunodeficiency diseases (e.g., AIDS).

- Patients with other active malignancies within the past five years, excluding
noninvasive skin or cervical carcinoma.

- Patients with any other serious medical or psychiatric illness that would prevent
informed consent.

- Patients with extensive chronic skin diseases such as extensive psoriasis, atopic
dermatitis, or xeroderma pigmentosa will be excluded from the Study.